Seres Therapeutics (NASDAQ:MCRB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The brokerage presently has a $12.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 22.57% from the company’s current price.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other equities analysts have also issued reports on MCRB. BidaskClub lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Cowen reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. Cantor Fitzgerald reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Wednesday, August 30th. ValuEngine lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Finally, Seaport Global Securities reaffirmed a “buy” rating and set a $20.00 price target on shares of Seres Therapeutics in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. Seres Therapeutics has an average rating of “Buy” and an average target price of $18.00.

Shares of Seres Therapeutics (NASDAQ:MCRB) traded down $0.08 on Tuesday, hitting $9.79. The company had a trading volume of 101,400 shares, compared to its average volume of 208,312. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The business had revenue of $23.00 million during the quarter, compared to analyst estimates of $17.29 million. During the same period in the previous year, the firm earned ($0.46) EPS. Seres Therapeutics’s quarterly revenue was up 76.9% compared to the same quarter last year. equities analysts forecast that Seres Therapeutics will post -2.33 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Seres Therapeutics by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock worth $17,911,000 after acquiring an additional 19,363 shares during the last quarter. Ark Investment Management LLC boosted its holdings in shares of Seres Therapeutics by 21.5% in the 2nd quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after buying an additional 135,276 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Seres Therapeutics by 39.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after buying an additional 106,479 shares during the last quarter. State Street Corp boosted its holdings in shares of Seres Therapeutics by 12.0% in the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after buying an additional 34,393 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Seres Therapeutics by 16.2% in the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after buying an additional 32,875 shares during the last quarter. 77.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Seres Therapeutics (MCRB) Stock Rating Upgraded by Zacks Investment Research” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/12/07/seres-therapeutics-mcrb-stock-rating-upgraded-by-zacks-investment-research.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.